Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kai Rejeski

Showing results (1-10 of 102) with videos related to

Pageof 11
Sort By:
Blood Advances|March 26, 2024
Navigating the prognostic role of transfusions after CAR-TMohammad Alhomoud, Kai Rejeski
The Lancet. Haematology|July 3, 2025
Off-the-shelf iPSC natural killer-cell therapy: a new chapter for B-cell lymphoma?Tobias Tix, Kai Rejeski
Transplantation and Cellular Therapy|October 9, 2025
Big spleens, low counts: a new prognostic signal in BCMA-directed CAR T-cell therapyMohammad Alhomoud, Kai Rejeski
Blood Advances|November 11, 2025
The CAR-HEMATOTOX: ready for prime timeJan H Frenking, Kai Rejeski
Oncogene|July 31, 2021
AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanismsKai Rejeski, Jesús Duque-Afonso, Michael Lübbert
Hematology. American Society of Hematology. Education Program|December 9, 2023
Recognizing, defining, and managing CAR-T hematologic toxicitiesKai Rejeski, Marion Subklewe, Frederick L Locke
Blood|May 12, 2026
How we prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignanciesKai Rejeski, Rahul Banerjee, Joshua A Hill
Haematologica|February 20, 2025
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategiesOfrat Beyar-Katz, Kai Rejeski, Roni Shouval
Transplantation and Cellular Therapy|April 19, 2023
Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple MyelomaKai Rejeski, Michael D Jain, Eric L Smith
Nature Medicine|July 16, 2025
Noncanonical and mortality-defining toxicities of CAR T cell therapyKai Rejeski, Joshua A Hill, Saurabh Dahiya, et al.
Pageof 11

Showing results (1-10 of 102) with videos related to

Sort By:
Pageof 11
Blood Advances|March 26, 2024
Navigating the prognostic role of transfusions after CAR-TMohammad Alhomoud, Kai Rejeski
The Lancet. Haematology|July 3, 2025
Off-the-shelf iPSC natural killer-cell therapy: a new chapter for B-cell lymphoma?Tobias Tix, Kai Rejeski
Transplantation and Cellular Therapy|October 9, 2025
Big spleens, low counts: a new prognostic signal in BCMA-directed CAR T-cell therapyMohammad Alhomoud, Kai Rejeski
Blood Advances|November 11, 2025
The CAR-HEMATOTOX: ready for prime timeJan H Frenking, Kai Rejeski
Oncogene|July 31, 2021
AML1/ETO and its function as a regulator of gene transcription via epigenetic mechanismsKai Rejeski, Jesús Duque-Afonso, Michael Lübbert
Hematology. American Society of Hematology. Education Program|December 9, 2023
Recognizing, defining, and managing CAR-T hematologic toxicitiesKai Rejeski, Marion Subklewe, Frederick L Locke
Blood|May 12, 2026
How we prevent infections in adults receiving bispecific antibody therapies for advanced B-cell malignanciesKai Rejeski, Rahul Banerjee, Joshua A Hill
Haematologica|February 20, 2025
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategiesOfrat Beyar-Katz, Kai Rejeski, Roni Shouval
Transplantation and Cellular Therapy|April 19, 2023
Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple MyelomaKai Rejeski, Michael D Jain, Eric L Smith
Nature Medicine|July 16, 2025
Noncanonical and mortality-defining toxicities of CAR T cell therapyKai Rejeski, Joshua A Hill, Saurabh Dahiya, et al.
Pageof 11